Since 2013, we have consistently demonstrated our ability to deliver
on our commitments, and 2018 was no exception. Our strong financial
performance supports the complex research required to meet today’s
health challenges, while delivering an industry-leading investment
return to shareholders.
For a complete look at our 2018 performance, our earnings press
release is located here.
Our pipeline was built for long-term growth, with programs chosen for
their potential to advance the treatment landscape and provide
innovative medicines to patients. We are entering a new phase of our
evolution where the strength of the pipeline will be clearly
demonstrated as a large number of our medicines become available.
Learn more about our pipeline here.
Science and innovation are the cornerstones of our business, and we
continue to make significant, strategic investments in R&D to
advance our pipeline. Learn more about the transformative science
AbbVie is supporting that could change the landscape of some of the
world’s most complex diseases here.
The combination of our innovation and commercial execution has
resulted in a portfolio of new and differentiated medicines that
benefit millions of patients across a large and growing number of
therapeutic areas. In 2018, almost a quarter of our revenue came from
products launched since separation.
Our strong execution has produced exceptional and industry-leading
shareholder value, delivering total shareholder returns of 235%*
A strong dividend is an important part of our investment identity,
and we have grown our quarterly dividend significantly since
Since 2013, we have built a strong foundation as a patient-focused
and high performing company. For us, the future is always present,
filled with the potential for advancing science and patient care. We
remain focused on discovering and delivering medicines where we have
proven expertise, while operating responsibly and positively impacting
the communities where we live and work.
For Investor and Media Use Only—Not For Promotional Use